Arrivent Biopharma Inc stock is traded at $12.23, with a volume of 1,102,409. It is down -9.34% in the last 24 hours and down -57.03% over the past month. ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Previous Close:
$13.49
Open:
$13.39
24h Volume:
1,102,409
Relative Volume:
0.58
Market Cap:
$603.03M
Revenue:
-
Net Income/Loss:
-$166.31M
P/E Ratio:
-
EPS:
-$4.46
Net Cash Flow:
-$160.59M
1W Performance:
-23.32%
1M Performance:
-57.03%
6M Performance:
-59.00%
1Y Performance:
-33.28%
1-Day Range:
$12.18$13.50
1-Week Range:
$12.18$14.99
52-Week Range:
$11.36$35.83
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma IncSector
HealthcareIndustry
BiotechnologyPhone
240-780-6356Address
18 CAMPUS BLVD., NEWTOWN SQUARE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS